Please check your internet connection and try again.
# Tabgenixim
## Overview
Tabgenixim is a synthetic peptide analog of somatostatin. It is primarily used for its antisecretory properties.
## Primary Indications
* Palliation of symptoms associated with metastatic neuroendocrine tumors (NETs), including carcinoid syndrome.
* Treatment of acromegaly.
## Adult Dosing
* **Neuroendocrine Tumors (Carcinoid Syndrome):** Typically initiated at 100 mcg subcutaneously three times daily. Dosage may be titrated upwards based on symptomatic response and tolerability, with potential increases to 200 mcg SC TID or even 300 mcg SC TID in some cases. Some patients may require higher doses.
* **Acromegaly:** Typically initiated at 10 mg intramuscularly every 4 weeks. Dosage may be adjusted based on IGF-1 levels and clinical response, with typical maintenance doses ranging from 10 mg to 30 mg IM every 4 weeks. Doses up to 40 mg IM every 4 weeks have been used.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be determined by a specialist based on individual patient factors.
## Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustments are routinely recommended, but caution is advised.
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to the drug or its components.
## Adverse Effects
* **Common:** Gastrointestinal disturbances (diarrhea, nausea, abdominal pain, vomiting), injection site reactions (pain, redness, swelling), fatigue, headache, hyperglycemia, hypoglycemia, gallstones.
* **Serious:** Severe gastrointestinal obstruction (especially with neuroendocrine tumors), cardiac arrhythmias, bradycardia, cholecystitis, cholestasis.
## Key Drug Interactions
* **Cyclosporine:** May decrease cyclosporine levels, potentially leading to graft rejection. Monitor cyclosporine levels and consider dose adjustment.
* **Bromocriptine:** May interfere with the absorption or efficacy of bromocriptine.
* **Drugs Affecting Heart Rate:** Caution when co-administered with other drugs that can cause bradycardia (e.g., beta-blockers).
## Monitoring
* **Disease-Specific:** Tumor markers (e.g., chromogranin A, 5-HIAA), imaging studies for tumor response, growth hormone and IGF-1 levels for acromegaly.
* **General:** Blood glucose levels (due to potential for hyperglycemia or hypoglycemia), liver function tests, gallbladder assessment (ultrasound), cardiac rhythm.
## Clinical Pearls
* Secretin stimulation tests are used to diagnose gastrinomas and should be performed prior to initiating therapy for suspected gastrinoma. Wait at least 24 hours after administration of Tabgenixim before performing the test.
* For NETs, Tabgenixim is primarily for symptomatic control, not curative.
* When switching from short-acting to long-acting formulations, consider the pharmacokinetics to ensure continuous coverage.
* Be aware of the potential for paradoxical worsening of diarrhea initially due to malabsorption.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and clinical guidelines before making treatment decisions. Local protocols may also influence dosing and management.
